Get A Quote Cellecta provides a Next-Generation Sequencing (NGS) human leukocyte antigen (HLA) typing solution, which uses the capabilities of hybrid capture technology. This dynamic workflow eliminates the inefficiencies and limitations associated with traditional Long-Range PCR methods. What are the Benefits? Enhanced Accuracy: Assay ensures improved allele balance and minimized dropout rates, resulting in higher precision Unparalleled Coverage: Benefit from maximum coverage of 17 loci, encompassing all exons for all genes, allowing for comprehensive analysis and identification of your desired HLA genotype Rapid 1-month turnaround from sample receipt to final report How Does it Work? The assay employs a clinically validated AlloSeq™ Tx workflow starting with genomic DNA. It begins by preparing a whole genome library using bead-bound transposons. Each sample is then indexed and pooled into a single tube. Biotinylated probes capture the genes of interest, enriching them for sequencing on an Illumina system. The resulting data is analyzed using the AlloSeq Assign software solution. Pair with T-cell Receptor (TCR) profiling The interaction between foreign antigens and T cells is facilitated by protein complexes called Major Histocompatibility Complexes (MHC), encoded by HLA genes. HLA type significantly influences T-cell selection and the composition of T-cell receptor (TCR) repertoires. Cellecta offers a TCR profiling service with its DriverMap™ Adaptive Immune Receptor (AIR) Repertoire technology that profiles all TCR- alpha, beta, gamma, and delta chains in a single multiplex RT-qPCR reaction. Combined immune receptor profiling and HLA typing can provide valuable insights into the human immune system and potentially improve patient outcomes by enabling more personalized treatment options. The assay is for Research Use Only (RUO). Applications of combined HLA typing and TCR profiling Identification of potential antigens: TCRs can recognize antigenic peptides presented by HLA proteins. By combining TCR profiling and HLA typing, researchers can gain a better understanding of how T cells recognize antigens and how this recognition can dictate disease outcomes. Improved neoepitope quality: Assessing HLA and TCR interfaces using specific pipelines can improve the quality of neoepitopes, which are important targets for cancer immunotherapy. Identification of disease mechanisms: The specificity of HLA-peptide to TCR is fundamental in enabling the adaptive immune system to mount an efficient and appropriate response to counteract diseases. Combined TCR profiling and HLA typing can help identify the molecular mechanisms that underpin the association between HLA genetics and functional outcomes. AlloSeq is a trademark of CareDx. All other trademarks are property of their respective owners. Tell us about your samples and request a quote
